{'fraction_non_alphanumeric': 0.059870550161812294, 'fraction_numerical': 0.045307443365695796, 'mean_word_length': 5.009708737864078, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
When a new definition overhauls perceptions of MAFLD related cirrhosis care.

HepatoBiliary Surg Nutr 2020;9(6):801-804 | http://dx.doi.org/10.21037/hbsn-20-725 Metabolic-associated fatty liver disease (MAFLD) (1), formerly known as non-alcoholic fatty liver disease, is a major causes of liver cirrhosis (2). MAFLD represents a growing global health and economic burden since approximately one in four people have the disease (3). As a consequence, MAFLD-related cirrhosis is expected to become the leading cause for liver failure and liver cancer, and the major indication for liver transplantation this century (3).